sec filing
RL
NASDAQ · RLMD
Relmada Therapeutics, Inc.
Healthcare · Biotechnology
$4.43
Up+$0.06 (+1.37%)
Updated Sep 6, 2026, 9:47 AM
SID Score
3.4/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 309.47M
- P/E ratio
- -2.07
- Dividend yield
- 0.00%
- 52-week range
- $4.29 – $8.00
- Volume
- 675.56K
- Avg. volume
- 1.02M
Price performance
RLMD price history
1M range · 20 trading sessions · Daily adjusted prices
RLMD closed at $4.43 after 20 trading sessions, down 2.42% for the selected period.
- Last close
- $4.43
- Period change
- -2.42%
- Period low
- $4.33
- Period high
- $4.85
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 4, 2026 | $4.35 | $4.44 | $4.32 | $4.43 | 675.56K |
| Sep 3, 2026 | $4.55 | $4.58 | $4.33 | $4.37 | 847.51K |
| Sep 2, 2026 | $4.54 | $4.5932 | $4.365 | $4.54 | 1.42M |
| Sep 1, 2026 | $4.31 | $4.51 | $4.31 | $4.46 | 944.06K |
| Aug 31, 2026 | $4.31 | $4.395 | $4.285 | $4.36 | 628.24K |
| Aug 28, 2026 | $4.51 | $4.53 | $4.32 | $4.33 | 678.36K |
| Aug 27, 2026 | $4.53 | $4.58 | $4.485 | $4.52 | 496.49K |
| Aug 26, 2026 | $4.57 | $4.60 | $4.46 | $4.55 | 476.69K |
| Aug 25, 2026 | $4.63 | $4.725 | $4.57 | $4.59 | 1.03M |
| Aug 24, 2026 | $4.64 | $4.64 | $4.375 | $4.58 | 935.75K |
| Aug 21, 2026 | $4.68 | $4.76 | $4.54 | $4.63 | 985.17K |
| Aug 20, 2026 | $4.74 | $4.79 | $4.55 | $4.64 | 1.03M |
| Aug 19, 2026 | $4.94 | $4.98 | $4.79 | $4.83 | 595.94K |
| Aug 18, 2026 | $4.75 | $4.86 | $4.71 | $4.85 | 751.7K |
| Aug 17, 2026 | $4.75 | $4.84 | $4.70 | $4.77 | 955.95K |
| Aug 14, 2026 | $4.74 | $4.835 | $4.68 | $4.80 | 925.43K |
| Aug 13, 2026 | $4.74 | $4.89 | $4.655 | $4.75 | 1.25M |
| Aug 12, 2026 | $4.52 | $4.81 | $4.51 | $4.72 | 1.66M |
| Aug 11, 2026 | $4.55 | $4.63 | $4.35 | $4.47 | 2.14M |
| Aug 10, 2026 | $4.91 | $4.9351 | $4.505 | $4.54 | 1.81M |
Latest RLMD news
The latest Smart Investors Daily articles mentioning RLMD.
Stock researchMarket Activity · Institutional Ownership
Loading stock research…